2023
Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study
Shah T, Abu-Much A, Batchelor W, Grines C, Baron S, Zhou Z, Li Y, Maini A, Redfors B, Hussain Y, Wollmuth J, Basir M, O'Neill W, Lansky A. Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study. JACC Cardiovascular Interventions 2023, 16: 1721-1729. PMID: 37409991, DOI: 10.1016/j.jcin.2023.04.036.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionFemale patientsIII studySex-based differencesImmediate PCISYNTAX scoreClinical outcomesMyocardial infarctionStroke/transient ischemic attackWorse renal functionAcute limb ischemiaTransient ischemic attackSex differencesPercutaneous coronary interventionAcute myocardial infarctionHigher ejection fractionCause deathCoronary complicationsIschemic attackMajor bleedingNonfemoral accessPercutaneous CoronaryPrior strokeCerebrovascular eventsVascular complications
2019
Sex Disparities in Cardiovascular Device Evaluations Strategies for Recruitment and Retention of Female Patients in Clinical Device Trials
Ghare MI, Chandrasekhar J, Mehran R, Ng V, Grines C, Lansky A. Sex Disparities in Cardiovascular Device Evaluations Strategies for Recruitment and Retention of Female Patients in Clinical Device Trials. JACC Cardiovascular Interventions 2019, 12: 301-308. PMID: 30732736, DOI: 10.1016/j.jcin.2018.10.048.Peer-Reviewed Original ResearchConceptsTrial participationClinical trialsClinical trial participationUnderrepresentation of womenMultistakeholder engagementGovernment agenciesFemale patientsFemale enrollmentCardiovascular trialsClinical research personnelNarrative reviewDevice trialsTrialsWomenParticipationPublic awarenessEducation campaigns
2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010, 5: 788-94. PMID: 20142192, DOI: 10.4244/eijv5i7a132.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPaclitaxelProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsTAXUS paclitaxel-eluting stentTarget vessel failureAngiographic late lossLate lossDiameter stenosisIII studyPooled analysisSPIRIT IIAdverse cardiac eventsSegment late lossStent late lossCoronary artery diseaseEES groupCardiac eventsArtery diseaseFemale patientsPES groupPatient levelClinical dataXIENCE VStent typeTwo-year analysisWomen
2004
801-2 Predictors of survival after primary percutaneous coronary intervention: The impact of myocardial perfusion grade in female patients
Costa R, Lansky A, Costantini C, Tsuchiya Y, Caluser C, Sahid B, Fahy M, Nikolsky E, Aymong E, Negoita M, Mehran R, Cox D, Grines C, Stone G. 801-2 Predictors of survival after primary percutaneous coronary intervention: The impact of myocardial perfusion grade in female patients. Journal Of The American College Of Cardiology 2004, 43: a266-a267. DOI: 10.1016/s0735-1097(04)91133-3.Peer-Reviewed Original Research